Weight loss
Oral Semaglutide in the EU: A New Weight Management Option
The recent approval of oral semaglutide (Rybelsus) for weight management in the European Union marks a significant development. This provides an additional option for individuals seeking medical support for weight loss, offering.
28 July 2026
DIRECT ANSWER
An online consultation lets an EU-licensed doctor review your case and, if appropriate, issue a prescription that is valid across the EU.
Less than 4 hours on average
Prescription issued in less than 4 hours on average if approved.
EU-licensed doctors
Every case is reviewed by a licensed clinician.
Valid across the EU
Approved prescriptions can be used at any EU pharmacy.
In this article
The recent approval of oral semaglutide for weight management in the European Union signifies an important advancement in treatment options. This development provides a non-injectable alternative to existing GLP-1 receptor agonists, potentially increasing accessibility and adherence for individuals seeking medical support for weight loss. It represents a new avenue for doctor-supervised weight management.
Key takeaways
- Oral semaglutide (Rybelsus) is now approved in the EU for weight management.
- This offers a non-injectable alternative to the existing injectable GLP-1 receptor agonists like Wegovy.
- The approval expands treatment options for individuals with obesity or overweight and related conditions.
- Access requires a medical prescription and doctor's assessment for suitability.
What is Oral Semaglutide and How Does it Work?
Oral semaglutide, marketed as Rybelsus, is an oral form of the GLP-1 receptor agonist semaglutide. It works by mimicking the effects of a natural hormone called glucagon-like peptide-1 (GLP-1), which plays a crucial role in appetite regulation and glucose metabolism. By activating GLP-1 receptors, it helps to reduce appetite, increase feelings of fullness, and slow stomach emptying, leading to reduced calorie intake and weight loss.How does it differ from injectable semaglutide (Wegovy)?
The primary difference between oral semaglutide (Rybelsus) and injectable semaglutide (Wegovy) lies in their administration method. Both contain the same active ingredient, semaglutide, but one is taken as a daily pill, while the other is administered as a weekly injection. The efficacy and safety profiles are broadly similar, though absorption and dosing schedules vary due to the oral formulation.Who is Eligible for Oral Semaglutide for Weight Management?
Eligibility for oral semaglutide for weight management aligns with general guidelines for GLP-1 receptor agonists. It is typically considered for adults with a Body Mass Index (BMI) of 30 kg/m² or greater (obesity), or those with a BMI of 27 kg/m² to <30 kg/m² (overweight) who also have at least one weight-related comorbidity such as type 2 diabetes, high blood pressure, or high cholesterol. A doctor's assessment is always required to determine individual suitability and rule out contraindications.What are the Potential Benefits and Considerations?
The availability of an oral GLP-1 receptor agonist offers several advantages. For individuals who prefer not to use injections, it provides a more convenient and potentially less daunting treatment option. This could lead to improved adherence to treatment plans and better long-term weight management outcomes. However, adherence to daily dosing and specific administration instructions (e.g., taking it with a small amount of water on an empty stomach at least 30 minutes before other food or drink) is crucial for its effectiveness.Clinical trials, such as the OASIS 1 study, have shown that oral semaglutide can lead to significant weight loss, with participants achieving an average of 15.1% body weight reduction over 68 weeks. This effect is comparable to the injectable forms.
Navigating Treatment Options: A Comparison
Choosing the right weight management medication involves considering individual preferences, medical history, and lifestyle. The table below outlines key aspects of various GLP-1 receptor agonists available for weight management in the EU.| Medication (Active Ingredient) | Formulation | Administration Frequency | Key Considerations |
|---|---|---|---|
| Oral Semaglutide (Rybelsus) | Tablet | Once daily | Non-injectable, strict administration requirements (empty stomach) |
| Injectable Semaglutide (Wegovy) | Pre-filled pen | Once weekly | Convenient weekly injection, widely studied for weight loss |
| Liraglutide (Saxenda) | Pre-filled pen | Once daily | Daily injection, established safety profile |
| Tirzepatide (Mounjaro) | Pre-filled pen | Once weekly | Dual GIP/GLP-1 agonist, potentially higher efficacy in some studies |
The Process for Obtaining a Prescription
Obtaining a prescription for oral semaglutide, like other prescription weight management medications, involves a medical assessment. This ensures the treatment is appropriate for your specific health profile and that you understand the potential benefits and risks. The process typically follows these steps:- Complete Medical Questionnaire
- Doctor Reviews Case
- Prescription Issued
- Present Prescription at EU Pharmacy
- Consultation Fee Refunded + Guidance
How Hi-Doctor can help
Hi-Doctor.ai offers a confidential and efficient online consultation service for weight management. Our EU-licensed doctors review your medical questionnaire within 24 hours to assess if treatments like oral semaglutide are clinically appropriate for you. If a prescription is issued, it will be a valid EU e-prescription (REMPE standard), recognizable in pharmacies across the EU. If our doctor determines that treatment is not appropriate, your consultation fee of EUR 25 is fully refunded. We provide consultations and prescriptions only; we do not sell or deliver medication.COMMON QUESTIONS
Frequently asked questions
No, oral semaglutide is not suitable for everyone. Its use is determined by a doctor based on individual health factors, including BMI, existing medical conditions, and other medications. A thorough medical assessment is essential to ensure its appropriateness and safety.
